Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
University of Chicago
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
City of Hope Medical Center
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
BTG International Inc.
Therapeutic Advances in Childhood Leukemia Consortium
South Plains Oncology Consortium
Milton S. Hershey Medical Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Institutes of Health Clinical Center (CC)
Therapeutic Advances in Childhood Leukemia Consortium
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute